Literature DB >> 18175050

IgA nephropathy associated with leukemia and lymphoma: report of two cases.

Osamu Motoyama1, Yasuko Kojima2, Akira Ohara2, Ichirou Tsukimoto2, Yukio Ishikawa3, Kikuo Iitaka4.   

Abstract

IgA nephropathy (IgAN) associated with leukemia and lymphoma has not, to our knowledge, been reported in children. Two children suffering from these diseases are described here. One patient developed IgAN at the end of 5 years' chemotherapy for acute lymphocytic leukemia. The other had microscopic hematuria 3 years before the onset of non-Hodgkin lymphoma, and hematuria continued during chemotherapy. Each disease occurred after a long interval, and the clinical courses did not run parallel. The association was thought to be incidental in our cases. Chemotherapy with adrenocorticosteroids and immunosuppressants [6-mercaptopurine (6-MP) and cyclophosphamide (CY)] for leukemia and lymphoma did not affect the clinical course of IgAN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175050     DOI: 10.1007/s10157-007-0009-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  8 in total

1.  Lymphomas and IgA nephropathy.

Authors:  C Cherubini; G Barbera; S D Di Giulio; A O Muda; T Faraggiana
Journal:  Nephrol Dial Transplant       Date:  2001-08       Impact factor: 5.992

2.  Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia.

Authors:  Yasunori Iwata; Takashi Wada; Akio Uchiyama; Atsuo Miwa; Izaya Nakaya; Tadashi Tohyama; Yuhji Yamada; Toshiro Kurokawa; Takashi Yoshida; Satoshi Ohta; Hitoshi Yokoyama; Hiroyuki Iida
Journal:  Intern Med       Date:  2006-12-15       Impact factor: 1.271

3.  IgA nephritis associated with mycosis fungoides. Report of two cases.

Authors:  G Ramirez; J B Stinson; E T Zawada; F Moatamed
Journal:  Arch Intern Med       Date:  1981-09

Review 4.  Successful treatment of IgA nephropathy in association with low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type.

Authors:  S K Mak; P N Wong; K Y Lo; A K Wong
Journal:  Am J Kidney Dis       Date:  1998-04       Impact factor: 8.860

5.  IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review.

Authors:  Jörg Bergmann; Dieter Buchheidt; Rüdiger Waldherr; Ole Maywald; Fokko J van der Woude; Rüdiger Hehlmann; Claude Braun
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

6.  Glomerular disease and urinary Sézary cells in cutaneous T-cell lymphomas.

Authors:  S M Moe; J M Baron; S Coventry; C Dolan; J G Umans
Journal:  Am J Kidney Dis       Date:  1993-05       Impact factor: 8.860

7.  [Non-Hodgkin lymphoma, IgA nephropathy and renal cell carcinoma].

Authors:  F Ceres; F Rivera; J L Yagüe; J Blanco; M García-Rojo; Ma D Sánchez de la Nieta; R Alcázar; M de la Torre
Journal:  Nefrologia       Date:  2003 Nov-Dec       Impact factor: 2.033

8.  Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma.

Authors:  Shinya Kimura; Akeyo Horie; Yoshiyuki Hiki; Chie Yamamoto; Satoru Suzuki; Junya Kuroda; Masayo Deguchi; Gen-ichi Kato; Takahiro Karasuno; Akira Hiraoka; Toshikazu Yoshikawa; Taira Maekawa
Journal:  Blood       Date:  2003-01-23       Impact factor: 22.113

  8 in total
  2 in total

1.  Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.

Authors:  Guangyan Nie; Lianqin Sun; Chengning Zhang; Yanggang Yuan; Huijuan Mao; Zhen Wang; Jianyong Li; Suyan Duan; Changying Xing; Bo Zhang
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

2.  Paraneoplastic immunoglobulin A nephropathy and associated focal segmental glomerulosclerosis in asymptomatic low volume B-cell lymphoma - a case report.

Authors:  Monica Suet Ying Ng; Leo Francis; Elango Pillai; Andrew John Mallett
Journal:  BMC Nephrol       Date:  2018-09-10       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.